GlassScriptPhysician profile
Adrian Del Boca
NPI 1215927496
$2,653.11
in general payments reported to CMS, 2019-2025
27 companies · $65.46 in 2025
The $65.46 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $106 · 2021: $763 · 2022: $814 · 2023: $436 · 2024: $50.35 · 2025: $65.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $693.61 | 2019-2025 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Abbvie INC. | $539.95 | 2019-2023 | Lo Loestrin Fe |
| Daiichi Sankyo INC. | $437.09 | 2019-2023 | Injectafer |
| Astellas Pharma US INC | $134.69 | 2022-2023 | Veozah |
| Myovant Sciences INC. | $119.64 | 2021-2022 | |
| Allergan, INC. | $93.08 | 2019-2020 | |
| Avion Pharmaceuticals | $76.68 | 2021-2023 | Balcoltra |
| Therapeuticsmd, INC. | $73.64 | 2019-2022 | |
| Coopersurgical, INC. | $72.05 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.93 | 2022 | |
| Axonics, INC. | $48.03 | 2023 | Axonics |
| Sumitomo Pharma America, INC. | $45.16 | 2023 | Myfembree |
| Lupin INC. | $31.12 | 2019-2020 | |
| Pfizer INC. | $21.64 | 2023 | |
| Shield Therapeutics INC | $19.87 | 2023 | Accrufer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $19.85 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.80 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.68 | 2019 | |
| Smith+Nephew, INC. | $17.83 | 2019 | |
| Scynexis, INC. | $16.90 | 2022 | |
| Mayne Pharma Commercial LLC | $16.02 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.50 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.38 | 2019 | |
| Mission Pharmacal Company | $14.25 | 2021 | |
| Abbott Laboratories | $13.95 | 2021 | |
| Merck Sharp & Dohme LLC | $13.75 | 2019 | |
| Covidien LP | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Del Boca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.